1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Viridian Therapeutics Inc (VRDN)
  7. Quote


Viridian Therapeutics Stock Price

-1.08 (-5.57%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 11,206
Bid Price 18.10
Ask Price 20.00
News -
Day High 19.30


52 Week Range


Day Low 17.2949
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Viridian Therapeutics Inc VRDN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.08 -5.57% 18.30 17:00:00
Open Price Low Price High Price Close Price Prev Close
19.12 17.2949 19.30 18.30 19.38
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
372 11,206 $ 18.39 $ 206,087 - 10.44 - 25.19
Last Trade Time Type Quantity Stock Price Currency
16:20:00 priorref 131 $ 18.30 USD


Draw Mode:

Viridian Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 397.52M 21.72M 21.68M $ 1.05M $ - -31.26 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.11M 8.00%

more financials information »

Viridian Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VRDN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week19.4119.9917.294919.4875,825-1.11-5.72%
1 Month18.3019.9917.12518.8280,1200.000.0%
3 Months12.7619.9910.4414.68243,4135.5443.42%
6 Months17.5519.9910.4414.50141,6390.754.27%
1 Year21.3925.1910.4415.0499,113-3.09-14.45%
3 Years21.3925.1910.4415.0499,113-3.09-14.45%
5 Years21.3925.1910.4415.0499,113-3.09-14.45%

Viridian Therapeutics Description

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Your Recent History
Viridian T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.